MarginsXMarginsX
Home › Markets › Health Care › ABT

Abbott Laboratories (ABT)

ABT trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$107.45
-0.99% on the day
Market cap
$186.1B
Large cap
Revenue · 2025
$44.3B
+5.7% on 2024
Net income · 2025
$6.5B
14.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABT on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000001800
SEC industry codePharmaceutical Preparations
Incorporated inIL

Financials · 2025

LineValue
Revenue$44.3B
Net income$6.5B
Operating income$8.1B
Net margin14.7%
Operating margin18.2%
Revenue growth+5.7%
Cash$8.5B
Total assets$86.7B
P/E (computed)28.5×
P/S (computed)4.2×

Warning signs

Cash runway
Cash-flow positive
$4.1B cash at September 30, 2026
Share count, 1 year
-0.4%
2025-09-30 to 2026-09-30 · -0.2% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$43.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$4.1B cash; operating cash flow $2.2B a quarter.Report 2026-09-30
Shares outstanding1,731,941,601 (2026-09-30); 1,738,871,947 a year earlier; 1,736,058,536 three years earlier.Cover page 2026-09-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-02-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Chicago, Illinois, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $4.4M, sold $47.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$13.0B$920.0M$1.7B$4.1B$31.2B$48.2B10-Q 2026-11-04
Q2 2026
2026-06-30
$12.6B$928.0M$2.5B$5.1B$32.6B$46.6B10-Q 2026-07-28
Q1 2026
2026-03-31
$11.2B$1.1B$1.3B$6.8B$34.0B$45.1B10-Q 2026-04-29
Q4 2025
2025-12-31
$11.5B$1.8B$3.3B$8.5B$12.9B$44.3B10-K 2026-02-20
Q3 2025
2025-09-30
$11.4B$1.6B$2.8B$7.5B$12.9B$43.8B10-Q 2026-11-04
Q2 2025
2025-06-30
$11.1B$1.8B$2.0B$7.0B$13.4B$43.1B10-Q 2026-07-28
Q1 2025
2025-03-31
$10.4B$1.3B$1.4B$6.5B$13.2B$42.3B10-Q 2026-04-29
Q4 2024
2024-12-31
$11.0B$9.2B$2.9B$7.6B$14.1B$42.0B10-K 2026-02-20

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-25
Latest annual report10-K2026-02-20
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxy
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
DEFA14A2026-03-13

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.3%
1 month+5.8%
3 months-2.5%
Year to date-13.4%
1 year-16.0%
From 52-week high-16.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
SNYSanofi ADS$48.39+0.04%$118.0B
NVSNovartis AG$160.20-0.19%$305.7B
GSKGSK plc$50.41-0.08%$102.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier